# Margin Analysis Schema — E42 Peptides

> Ready to fill when Rayan provides COGS data. All formulas are manual for now (markdown table), can be ported to a spreadsheet/Notion if needed.

## Products & Current Pricing

| Product | Sell Price (AUD) | COGS | Gross Margin | Markup % | Price Floor (30%) | At Compet Price | Margin at Compet |
|---------|-----------------|------|-------------|----------|-------------------|----------------|-----------------|
| BPC-157 5mg | $102.30 | _TBD_ | _TBD_ | _TBD_ | _TBD_ | $79.76 | _TBD_ |
| TB-500 5mg | $150.00 | _TBD_ | _TBD_ | _TBD_ | _TBD_ | $109.00 | _TBD_ |
| NAD+ 500mg | $230.00 | _TBD_ | _TBD_ | _TBD_ | _TBD_ | _TBD_ | _TBD_ |
| Semax 0.1% 10ml | $79.76 | _TBD_ | _TBD_ | _TBD_ | _TBD_ | _TBD_ | _TBD_ |
| Selank 0.1% 10ml | $79.76 | _TBD_ | _TBD_ | _TBD_ | _TBD_ | _TBD_ | _TBD_ |
| Retatrutide 10mg | $160.00 | _TBD_ | _TBD_ | _TBD_ | _TBD_ | $199.00 | _TBD_ |
| Tirzepatide 10mg | $160.00 | _TBD_ | _TBD_ | _TBD_ | _TBD_ | _TBD_ | _TBD_ |
| Glow Blend | $201.44 | _TBD_ | _TBD_ | _TBD_ | _TBD_ | _TBD_ | _TBD_ |

## Formulas
- **Gross Margin** = (Sell Price − COGS) / Sell Price × 100
- **Markup %** = (Sell Price − COGS) / COGS × 100
- **Price Floor (30%)** = COGS / (1 − 0.30) — minimum price to maintain 30% margin

## COGS Components (Fill Per Product)
- Raw material (peptide compound)
- Vial/bottle/packaging
- COA testing (batch cost ÷ units)
- Shipping from supplier
- Payment processing (≈2-5% depending on method)
- Any Australian import duties/taxes

## What-If Scenarios

### Scenario A: Keep Current Prices
Compute actual margins. If margins are 60%+ at current prices, competitive reduction is safe.

### Scenario B: Match Competitor Prices
- BPC-157 at $79.76 → needs COGS ≤ $55.83 for 30% margin
- TB-500 at $109.00 → needs COGS ≤ $76.30 for 30% margin

### Scenario C: Premium Pricing (if quality justifies it)
- Maintain current prices but add value (batch-specific COAs, free shipping)
- Targeted at quality-conscious researchers (not price-shoppers)

## Industry Benchmarks
| Segment | Typical Margin | Notes |
|---------|---------------|-------|
| Research peptides | 50-70% | COGS is low, value is in curation + trust |
| Supplements | 40-60% | Higher customer acquisition cost |
| Pharma | 80-90% | Different business model |
| AU-specific | 50-65% | Smaller market, fewer competitors |

## When Rayan Provides COGS
1. Fill the TBD cells in the table above
2. Recompute margins
3. If margins at current prices ≥ 60% → competitive reduction is safe (recommend adjusting)
4. If margins are 40-60% → consider value-add instead of price cut
5. If margins < 40% → do NOT cut prices; find supply chain savings first